G1/G2 Rule
G1/G2ルール

In the FY2018 drug price revision in April 2018, the MHLW is drastically revamping its re-pricing scheme for long-listed products (LLPs) (長期収載品; choki shusai hin), or off-patent brand-name drugs, as it hopes to further accelerate Japan’s shift from LLPs to...

To read the full story

LEXICON

Elective Care Scheme for LLPs長期収載品選定療養制度
July 19, 2024
New PMP Criteria新薬創出加算の新要件
March 9, 2018
Cost-Based Method原価計算方式
July 27, 2017
Sakigake Designation Scheme先駆け審査指定制度
August 17, 2016
Special expansion re-pricing (Huge-seller re-pricing)特例拡大再算定（巨額再算定）
March 4, 2016

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo Backs Draft FY2026 Pricing Reform Outline, Rejects Key Industry Requests

By Takashi Ebisawa

The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…

COLUMN

AI: Your New HR BFF (Not Your Replacement!)

By Philip Carrigan

Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…

COMMENTARY

Radioligand Therapy Faces Capacity Bottleneck in Japan, System Build-Out Needed to Deliver on Promise

By Koji Shimomura

Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…